Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2019—Quest Diagnostics and Oxford Immunotec announced that Quest has completed its acquisition of the U.S. laboratory services business of Oxford Immunotec; the T-Spot.TB tuberculosis and the Accutix tick-borne disease testing services are now part of Quest’s portfolio of infectious disease testing services.
January 2019—Illumina announced it will acquire Pacific Biosciences for approximately $1.2 billion.
January 2019—Hologic announced the availability of Open Access functionality for its Panther Fusion system. This enhanced functionality will allow CLIA-certified laboratories to develop laboratory-developed tests to run on the fully automated Fusion platform.
January 2019—The FDA has accepted Roche’s supplemental biologics license application and granted priority review to the company’s Tecentriq in combination with Abraxane (nab-paclitaxel, Celgene) for the initial treatment of people with PD-L1-positive, metastatic triple-negative breast cancer.
January 2019—Bio-Rad has announced its InteliQ selection of quality controls, available in barcoded, load-and-go tubes. This new configuration is designed to help optimize workflow efficiency and improve the laboratory’s risk management program.
January 2019—Genomic Testing Cooperative announced it will offer multiple laboratory-developed genomic profiling tests for hematologic and solid tumors using next-generation sequencing technology.
January 2019—The FDA approved Truxima (rituximab-abbs, Celltrion) as the first biosimilar to Rituxan (rituximab, Genentech) for patients with CD20-positive, B-cell non-Hodgkin lymphoma to be used as a single agent or in combination with chemotherapy.
January 2019—Ortho Clinical Diagnostics’ Vitros Immunodiagnostic Products HIV Combo Reagent Pack and Calibrator received FDA approval for use on Ortho’s Vitros 5600 Integrated System.
December 2018—Beckman Coulter launched Kaluza C Flow Cytometry Analysis Software, which aims to streamline clinical QC reporting and address standardization issues in flow cytometry. Kaluza C improves the visualization and analysis of rare events. It makes it possible to process large, multicolor files with up to 20 million events and set the plot resolution according to the gate level. The software enables the operator to focus on a limited number of events to preserve the integrity of the scatterplot.
December 2018—Mawi DNA Technologies launched its iSwab-Cells cell stabilization product line. Designed to collect and stabilize intact cells for up to four weeks at room temperature, the sample collection system enables users to perform multiple omics analyses from the same sample.
